will quarter many otherwise primarily and historical morning of senior outstanding followed review in focus by by majority quarter which This indebtedness completed the will was the Collegium, the the transactions our to I convertible from of our any the was the completed repayment to and non-GAAP Gralise of first tender all My clouded our Year-over-year that in limit highlights our are April. the Therefore, the noted. comparisons sale first sale including on portion of our XXXX. the NUCYNTA quarter-over-quarter notes, comments results I'll Arthur. we the of discussion of continuing of business. secured of repurchase the you, to comparisons financial Thank unless Alvogen,
decision pending merger financial at any as well key factors Zyla of guidance providing the as this COVID-XX. which time. be to our two are not will we overall impact are There with Also this contributing
$XX.X the agreement the million reported from sale. of of In This NUCYNTA we revenues close our to revenues. million recorded GAAP included that total prior Collegium were quarter, commercialization first $XX.X of
also non-GAAP million from $X.X included which is EBITDA. of excluded divested adjusted our adjustments sales and Gralise accrual product other results or Our
neurology shifts made inventory in last sales reflection business are from comparison in our quarter totaled a Our These versus year has $XX results million product CAMBIA fourth and in and experienced that year-over-year prior difficult. Zipsor million in the quarter. fluctuations have our These inventory two first primarily $X.X of channel levels the years. in $XX.X the million period our
anticipated COVID-related CAMBIA for our first half be with expected Zipsor results broadly taking to year we line XXXX, for prior this into planning had any impact. the and before account and In in
our the in This did in believe for retailers April. the quarter, that quarter by this happened Late products not such any because patients until caused that both buying first and disruptions we late were see of COVID-XX. we products advanced anticipated increase of
are the channel patient programs invest they access continue ensure In in when behind receive our to addition to both we discount our inventories, to medicines in shifts to prescribed. that products patients
and behalf Alvogen Considering prescription X.X% and that by demand On result up on of a to the the representatives Symphony was year-over-year. sales strong CAMBIA in Due all to mid-March pulled and COVID-XX, of this from promoting we was Gralise for our field a also X.X% more telephonic quarter in Zipsor their indicative of products. in promotions we up reported basis the were the is territories. physicians underlying shifted still Health, our demand as with total
impact that predict point, the it's to too business. our COVID-XX early still this At on have may
our and that the we been chain However, not we to believe date. have inventories near-term impacted supply adequate materially has for
prior the costs depreciation and million transaction defined reported GAAP relative XX.X% stock-based first and XX.X%, opioid $XX.X in quarter, a of respectively. $XX.X in reduction litigation million prior incurred operating non-GAAP In as year compensation we of quarter expenses costs, to million operating less and the amortization expenses $XX.X the
As see end accelerated of implemented year. to we're track on savings we at cost million last you the the realize in can $XX well
COVID-XX taken that may we've cost any due April result. action base further weather disruption addition, further reduce In in to our to to
$X.X NUCYNTA and year EBITDA reduction to on $XX.X EBITDA of NUCYNTA. adjusted in does agreement of February is of commercialization $XX.X were from year-over-year to the adjusted fully reflective The Gralise XXth. received reflect prior period million which reported sale prior the We revenues million the Collegium that the of sales million, of the non-GAAP closing of
out was XXth. the $XX.X the quarter, which million our adjusted received sales, from only fully results. January Alvogen's reflecting owed Alvogen we on receipts from from included these EBITDA royalty that recorded our on Excluded results gain of the us GAAP a Of EBITDA for and of close the Alvogen, backed $X.X partial for month have we purposes, January the the sale in was Gralise in reflective million which on to
in balance only Following receivable reduction the quarter debt. completed Subsequent reflecting debt assets a intangible on end, is royalty remaining to the with the and our the far simpler, in we transactions sheet addition Gralise. of our tender quarter, of the
convertible in All million principal. over debt tendered our at saved was repurchased us $X.X XX.X%. either This of or
on privately saved I that cash $X flow. interest repurchase cash also approximately focus by We to have exemplifies tender. and agreements the and million in Arthur negotiated the completing prior This the
that expect we next soon of like and to Assertio refinancing the large comments. instrumental his of with also with team transactions to in we've to that, point Zyla of all Everyone making done the job The a August possible. I'd year role conclude has close, and thank And I a with completed started the reposition at month. I Before last in you. in tremendous Arthur reiterate made acquisition here played company an here has the of number that this help
marketplace to have in to would frame, and also is for As vision, leadership did colleagues in thank in be a If the it Zyla it. which weren't possible the forward that company and from remiss we this sustainable constant our not encouragement Arthur. time new welcome building we growth-oriented especially begin to his current well-positioned look been not I'd
prepared our remarks. Max And for That back turn comments. to the ends I'll closing call
